NIH Clinical Trial Testing Remdesivir Plus Interferon Beta-1a for COVID-19 Treatment Begins | NIH: National Institute of Allergy and Infectious Diseases

NIH Clinical Trial Testing Remdesivir Plus Interferon Beta-1a for COVID-19 Treatment Begins | NIH: National Institute of Allergy and Infectious Diseases

NIAID Clinical Trial Testing Remdesivir Plus Interferon Beta-1a for COVID-19 Treatment Begins

A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen consisting of the antiviral remdesivir plus the immunomodulator interferon beta-1a in people with COVID-19 has begun. The NIAID-sponsored study, called the Adaptive COVID-19 Treatment Trial 3 (ACTT 3), is anticipated to enroll more than 1,000 hospitalized adults with COVID-19 at as many as 100 sites in the United States and abroad.